Prognostic Value of Laboratory Biomarkers in Risk Stratification for Short-Term Outcomes in Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis
Key Points
Prognostic biomarkers enhance the understanding of short-term outcomes in hemophagocytic lymphohistiocytosis.
Risk stratification based on laboratory biomarkers may lead to better management and treatment.
Laboratory analysis of biomarkers shows promise for predicting outcomes associated with Epstein-Barr virus.
Markers identified can help categorize patients based on severity and likely disease progression.
Prognostic Value of Laboratory Biomarkers in Risk Stratification for Short-Term Outcomes in Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis | Synapse
Also Consider
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: